Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Abbott has officially opened Abbott Biotechnology Limited (ABL), the new state-of-the-art biologics manufacturing facility in Puerto Rico that will support the long-term supply of a leading biologic agent, HUMIRA® (adalimumab). The Governor of Puerto Rico was on hand to dedicate the new facility, which received U.S. Food and Drug Administration approval in February to commercially produce HUMIRA for the U.S. market.
ABL becomes the main production facility for HUMIRA, with significantly more production capacity than the other manufacturing facility for HUMIRA, the Abbott Biotechnology Center (ABC) in Worcester, Massachusetts. The ABC site will now serve as a supporting production facility for HUMIRA and will focus on Abbott’s growing biologics research and development portfolio.
ABL is Abbott’s single-largest capital investment to date, costing approximately $450 million. In addition to producing HUMIRA, the 330,000-sq.-ft. facility is designed for large-scale production of future products in Abbott’s pipeline through its’ advanced manufacturing technology.
Learn more about this important addition to Abbott’s manufacturing capabilities.
|
The new Abbott Biotechnology Limited (ABL) facility in Barceloneta, Puerto Rico, is the single-largest capital investment in Abbott’s history. |
A laboratory technician at the Abbott Biotechnology Limited (ABL) facility performs the microbial analysis inside an isolator chamber. |
In the Abbott Biotechnology Limited (ABL) facility, technicians prepare a portable solution tank used in the biologics manufacturing process. |
Operator working in the process control system computer to transfer the solution to a process tank. |
Humira Important Safety Information and Humira US Prescribing Information.
More information regarding HUMIRA.
